Tanabe Pharma America Completes Transfer of RADICAVA Business to Shionogi Tanabe Pharma America finalizes the transfer of RADICAVA to Shionogi, ensuring the therapy's continued growth and support for ALS patients.

Tanabe Pharma America Completes Transfer of RADICAVA Business to Shionogi #USA #Jersey_City #RADICAVA #Shionogi #Tanabe_Pharma

Tanabe Pharma America Transfers RADICAVA® Business to Shionogi for Growth and Innovation Tanabe Pharma America has announced the transfer of RADICAVA® business to Shionogi, aiming for enhanced focus on growth and solutions for ALS patients.

Tanabe Pharma America Transfers RADICAVA® Business to Shionogi for Growth and Innovation #United_States #Jersey_City #RADICAVA #Shionogi #Tanabe_Pharma

Mitsubishi Tanabe Pharma America to Present New Neurodegenerative Research Findings at AAN 2025 Annual Meeting Mitsubishi Tanabe Pharma America will showcase 11 studies at AAN 2025, focusing on breakthroughs in Parkinson's and ALS therapies.

Mitsubishi Tanabe Pharma America to Present New Neurodegenerative Research Findings at AAN 2025 Annual Meeting #United_States #San_Diego #Mitsubishi_Tanabe #RADICAVA #ND0612

Mitsubishi Tanabe Pharma America Highlights Innovative ALS Research at Major Symposium in Canada Mitsubishi Tanabe Pharma America will showcase significant ALS research findings at the MNDA's 35th International Symposium, emphasizing their commitment to ALS treatment advancements.

Mitsubishi Tanabe Pharma America Highlights Innovative ALS Research at Major Symposium in Canada #USA #ALS_Research #Jersey_City #Mitsubishi_Tanabe #RADICAVA